Table 7.
Bacterial spectrum and resistance (R) against nitroxoline (Ni) versus controls (C), cotrimoxazole or norfloxacin, at study entry (visit 1)
| Study Nr./R | NWNF 10 | R(n) | NWNF 11 | R(n) | NWNF 13 | R(n) | NWNF 15 | R(n) | NWNF 10–13 | R(n) | NWNF 10–15 | R(n) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacterial isolates | n (%) | Ni/C | n (%) | Ni/C | n (%) | Ni/C | n (%) | Ni/C | n (%) | Ni/C | n (%) | Ni/C |
| E. coli | 82(67.2%) | -/1 | 88(65.3%) | 1/6 | 81(67.0%) | −/− | 98(73.0%) | −/− | 251(66.4%) | 1/7 | 349(68.2%) | 1/7 |
| Proteus spp.* | 20(16.4%) | −/− | 9(6.7%) | −/− | 8(6.6%) | −/− | 12(9.0%) | −/− | 37(9.8%) | −/− | 49(9.6%) | −/− |
| Klebsiella spp. | 1(0.8%) | −/− | 5(3.7%) | −/− | 1(0.8%) | −/− | 6(4.5%) | −/− | 7(1.9%) | −/− | 13(2.5%) | −/− |
| Enterobacter spp. | - | - | 2(1.5%) | −/− | 3(2.5%) | −/− | 7(5.2%) | -/2 | 5(1.3%) | −/− | 12(2.3%) | -/2 |
| Citrobacter spp. | 2(1.6%) | −/− | - | −/− | 1(0.8%) | −/− | 1(0.8%) | −/− | 3(0.8%) | −/− | 4(0.8%) | −/− |
| Enterococci | 9(7.4%) | −/− | 13(9.7%) | 6/1 | 13(10.7%) | -/1 | 2(1.5%) | −/− | 35(9.3%) | 6/2 | 37(7.2%) | 6/2 |
| Staphylococci | 5(4.1%) | −/− | 7(5.2%) | −/− | 13(10.7%) | 1/- | 8(6.0%) | −/− | 25(6.6%) | 1/- | 33(6.4%) | 1/- |
| Streptococci | 2(1.6%) | −/− | 2(1.5%) | −/− | 1(0.8%) | −/− | - | −/− | 5(1.3%) | −/− | 5(1.0 %) | −/− |
| Others | 1(0.8%) | −/− | 9(6.7%) | −/− | - | −/− | - | −/− | 10(2.6%) | −/− | 10(2.0%) | −/− |
| Total | 122(100%) | -/1 | 135(100%) | 7/7 | 121(100%) | 1/1 | 134(100%) | -/2 | 378(100%) | 8/9 | 512(100%) | 8/11 |
| -/0.8% | 5.2/5.2% | 0.8/0.8% | -/1.5% | 2.1/2.4% | 1.6/2.1% | |||||||
| Isolates/patients | 122/122 | 135/115 | 121/105 | 134/116 | 378/350 | 512/466 | ||||||
| (1.0) | (1.17) | (1.15) | (1.16) | (1.08) | (1.1) |
*indol positive and negative strains.